SK Biopharmaceuticals Q3 Operating Profit Rises 65.9% Year-on-Year

PUBT · 1d ago
SK Biopharmaceuticals Q3 Operating Profit Rises 65.9% Year-on-Year
  • SK Biopharmaceuticals’ third-quarter 2026 operating profit rose 65.9% year over year to KRW 116.28 billion.
  • Revenue increased 34.8% from a year earlier to KRW 258.42 billion.
  • Net profit fell 23.9% year over year to KRW 54.34 billion.
  • For the first nine months of 2026, operating profit climbed 92.3% to KRW 303.12 billion.
  • Nine-month revenue grew 43.2% to KRW 733.67 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SK Biopharmaceuticals Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800127), on November 05, 2026, and is solely responsible for the information contained therein.